GST will benefit the consumers as the prices of diabetes and cancer reduces

New Delhi : The National Pharmaceutical Pricing Authority (NPPA) announced provisional ceiling price of 761 medicines including drugs to treat Cancer, HIV, Diabetes and antibiotics. To make implementation of GST smooth, NPPA have worked out to release the provisional ceiling prices of 761 formulations.

Pharmaceutical firms asked by NPPA to go through the list and inform them by June 29 if any correction has to be made. Prices will make public after GST implementation.

NPPA said the expected tax range of 2-3 percent after the rollout of the new indirect tax, depending on the states.  Prices of the anti-cancer drugs like Bortezomib, Docetaxel and Gemcitabine have been reduced in the provisional list.

The goods and services tax (GST), is the biggest indirect tax reform and definitely help patients of diabetes and cancer patients who need medicines on regular basis.

The price of the Trastuzumab injection pack used to treat Breast will be down at Rs 54,582.25 after July 1, was Rs 56,912.83 earlier. Other anti-cancer drugs like Bortezomib, Docetaxel and Gemcitabine have been reduced in the shared list.

In short, the cancer and diabetes patients will get benefit after GST implementation.

LEAVE A REPLY

Please enter your comment!
Please enter your name here